Human Immunodeficiency Virus (HIV) transmission through genital and rectal mucosa has led to intensive study of mucosal immune responses to HIV and to the development of a vaccine administered locally. However, HIV transmission through the oral mucosa is a rare event. The oral mucosa represents a physical barrier and contains immunological elements to prevent the invasion of pathogenic organisms. This particular defense differs between micro-compartments represented by the salivary glands, oral mucosa, and palatine tonsils. Secretory immunity of the salivary glands, unique features of cellular structure in the oral mucosa and palatine tonsils, the high rate of oral blood flow, and innate factors in saliva may all contribute to the resistance to HIV/Simian Immunodeficiency Virus (SIV) oral mucosal infection. In the early stage of HIV infection, humoral and cellular immunity and innate immune functions in oral mucosa are maintained. However, these particular immune responses may all be impaired as a result of chronic HIV infection. A better understanding of oral mucosal immune mechanisms should lead to improved prevention of viral and bacterial infections, particularly in immunocompromised persons with Acquired Immune Deficiency Syndrome (AIDS), and to the development of a novel strategy for a mucosal AIDS vaccine, as well as vaccines to combat other oral diseases, such as dental caries and periodontal diseases.
Get full access to this article
View all access options for this article.
References
1.
Anil S, Challacombe SJ (1997). Oral lesions of HIV and AIDS in Asia: an overview. Oral Dis3(Suppl 1):S36–S40.
2.
Archibald DW, Zon L, Groopman JE, McLane MF, Essex M (1986). Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS. Blood67:831–834.
3.
Archibald DW, Barr CE, Torosian JP, McLane MF, Essex M (1987). Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complex. J Infect Dis155:793–796.
4.
Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphey-Corb M, et al. (1996). Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science272:1486–1489.
5.
Baron S, Poast J, Cloyd MW (1999). Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med159:303–310.
6.
Barr CE, Miller LK, Lopez MR, Croxson TS, Schwartz SA, Denman H, et al. (1992). Recovery of infectious HIV-1 from whole saliva. J Am Dent Assoc123:36–48.
7.
Bergey EJ, Cho MI, Blumberg BM, Hammarskjold ML, Rekosh D, Epstein LG, et al. (1994). Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr7:995–1002.
8.
Bernstein JM, Baekkevold ES, Brandtzaeg P (2005). Immunobiology of the tonsils and adenoids. In: Mucosal immunology. 3rd ed. Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Amsterdam: Elsevier/Academic Press, pp. 1547–1572.
9.
Brandtzaeg P, Fjellanger I, Gjeruldsen ST (1970). Human secretory immunoglobulins. I. Salivary secretions from individuals with normal or low levels of serum immunoglobulins. Scand J Haematol Suppl12:3–83.
10.
Bukawa H, Sekigawa K, Hamajima K, Fukushima J, Yamada Y, Kiyono H, et al. (1995). Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat Med1:681–685.
11.
Burkhardt A (1992). Intraepithelial lymphocytes and Langerhans cells in the oral mucosa—dynamic aspects. J Dent Assoc S Afr47:200–203.
12.
Butler JE, Spradling JE, Peterman JH, Joshi KS, Satam M, Challacombe SJ (1990). Humoral immunity in root caries in an elderly population. 1. Oral Microbiol Immunol5:98–107.
13.
Canady JW, Johnson GK, Squier CA (1993). Measurement of blood flow in the skin and oral mucosa of the rhesus monkey (Macaca mulatta) using laser Doppler flowmetry. Comp Biochem Physiol Comp Physiol106:61–63.
14.
Chen JW, Flaitz CM, Wullbrandt B, Sexton J (2003). Association of dental health parameters with oral lesion prevalence in human immunodeficiency virus-infected Romanian children. Pediatr Dent25:479–484.
15.
Chiang CP, Chueh LH, Lin SK, Chen MY (1998). Oral manifestations of human immunodeficiency virus-infected patients in Taiwan. J Formos Med Assoc97:600–605.
16.
Chidzonga MM, Rusakaniko S (2004). Ranula: another HIV/AIDS associated oral lesion in Zimbabwe? Oral Dis10:229–232.
17.
Childers NK, Tong G, Li F, Dasanayake AP, Kirk K, Michalek SM (2002). Humans immunized with Streptococcus mutans antigens by mucosal routes. J Dent Res81:48–52.
18.
Chou LL, Epstein J, Cassol SA, West DM, He W, Firth JD (2000). Oral mucosal Langerhans’ cells as target, effector and vector in HIV infection. J Oral Pathol Med29:394–402.
19.
Cohen MS, Shugars DC, Fiscus SA (2000). Limits on oral transmission of HIV-1. Lancet356:272.
20.
Coogan MM, Sweet SP, Challacombe SJ (1994). Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun62:892–896.
21.
Coppenhaver DH, Sriyuktasuth-Woo P, Baron S, Barr CE, Qureshi MN (1994). Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N Engl J Med330:1314–1315.
22.
Crama-Bohbouth G, Lems-van Kan P, Weterman IT, Biemond I, Pena AS (1984). Immunological findings in whole and parotid saliva of patients with Crohn’s disease and healthy controls. Dig Dis Sci29:1089–1092.
23.
Crawford JM, Taubman MA, Smith DJ (1975). Minor salivary glands as a major source of secretory immunoglobin A in the human oral cavity. Science190:1206–1209.
24.
Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J (1998). Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J Exp Med187:25–35.
25.
Cui Z, Mumper RJ (2002). Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm Res19:947–953.
26.
Czerkinsky C, Anjuere F, McGhee JR, George-Chandy A, Holmgren J, Kieny MP, et al. (1999). Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev170:197–222.
27.
De Buysscher EV, Dubois PR (1978). Detection of IgA anti-Escherichia coli plasma cells in the intestine and salivary glands of pigs orally and locally infected with E. coli. Adv Exp Med Biol107:593–600.
28.
Deslauriers N, Neron S, Mourad W (1985). Immunobiology of the oral mucosa in the mouse. Immunology55:391–397.
29.
Desvignes C, Esteves F, Etchart N, Bella C, Czerkinsky C, Kaiserlian D (1998). The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo. Clin Exp Immunol113:386–393.
30.
Emmelin N, Gjørstrup P (1973). On the function of myoepithelial cells in salivary glands. J Physiol230:185–198.
31.
Espinoza I, Rojas R, Aranda W, Gamonal J (2003). Prevalence of oral mucosal lesions in elderly people in Santiago, Chile. J Oral Pathol Med32:571–575.
32.
Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D (1997). Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol78(Pt 7):1577–1580.
33.
Etchart N, Desmoulins PO, Chemin K, Maliszewski C, Dubois B, Wild F, et al. (2001). Dendritic cells recruitment and in vivo priming of CD8+ CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein. J Immunol167:384–391.
34.
Fan M, Bian Z, Peng Z, Guo J, Jia R, Chen Z (2002). DNA vaccine encoding Streptococcus mutans surface protein protected gnotobiotic rats from caries. Zhonghua Kou Qiang Yi Xue Za Zhi37:4–7.
35.
Figueroa CD, Marchant A, Novoa U, Forstermann U, Jarnagin K, Scholkens B, et al. (2001). Differential distribution of bradykinin B(2) receptors in the rat and human cardiovascular system. Hypertension37:110–120.
36.
Foltyn P (1993). Dry mouth in HIV infection. Med J Aust159:355.
37.
Frankel SS, Wenig BM, Burke AP, Mannan P, Thompson LD, Abbondanzo SL, et al. (1996). Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science272:115–117.
38.
Frankel SS, Tenner-Racz K, Racz P, Wenig BM, Hansen CH, Heffner D, et al. (1997). Active replication of HIV-1 at the lymphoepithelial surface of the tonsil. Am J Pathol151:89–96.
39.
Galkina E, Tanausis K, Preece G, Tolaini M, Kioussis D, Florey O, et al. (2003). L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med198:1323–1335.
40.
Gebert A (1997). M cells in the rabbit palatine tonsil: the distribution, spatial arrangement and membrane subdomains as defined by confocal lectin histochemistry. Anat Embryol (Berl)195:353–358.
41.
Gillespie GM, Marino R (1993). Oral manifestations of HIV infection: a Panamerican perspective. J Oral Pathol Med22:2–7.
42.
Glick M, Muzyka BC, Lurie D, Salkin LM (1994). Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol77:344–349.
43.
Glushakova S, Baibakov B, Margolis LB, Zimmerberg J (1995). Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med1:1320–1322.
44.
Gorfien JL, Noble B, Brodsky L (2001). Comparison of the microanatomical distributions of macrophages and dendritic cells in normal and diseased tonsils. Ann Otol Rhinol Laryngol110:173–182.
45.
Goto Y, Yeh CK, Notkins AL, Prabhakar BS (1991). Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. AIDS Res Hum Retroviruses7:343–347.
46.
Grbic JT, Singer RE, Jans HH, Celenti RS, Lamster IB (1995). Immunoglobulin isotypes in gingival crevicular fluid: possible protective role of IgA. J Periodontol66:55–61.
47.
Grbic JT, Lamster IB, Fine JB, Lam KS, Celenti RS, Herrera-Abreu M, et al. (1999). Changes in gingival crevicular fluid levels of immunoglobulin A following therapy: association with attachment loss. J Periodontol70:1221–1227.
48.
Hämmerle CH, Schiødt M, Lackner AA, Armitage GC, Daniels TE, Greenspan JS (1993). Langerhans cells in oral mucosa of rhesus monkeys before and after infection by simian retrovirus-1 and simian immunodeficiency virus. Oral Surg Oral Med Oral Pathol76:742–745.
49.
Hasséus B, Jontell M, Bergenholtz G, Dahlgren UI (2004). Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin. Clin Exp Immunol136:483–489.
50.
Hibino T, Takemura T, Sato K (1994). Human eccrine sweat contains tissue kallikrein and kininase II. J Invest Dermatol102:214–220.
51.
Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, et al. (1997). High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses13:1179–1185.
52.
Hurlimann J, Zuber C (1968). In vitro protein synthesis by human salivary glands. I. Synthesis of salivary IgA and serum proteins. Immunology14:809–817.
53.
Hussain LA, Lehner T (1995). Comparative investigation of Langerhans’ cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology85:475–484.
54.
Jackson DE, Lally ET, Nakamura MC, Montgomery PC (1981). Migration of IgA-bearing lymphocytes into salivary glands. Cell Immunol63:203–209.
55.
Jansma J, Vissink A, ’s-Gravenmade EJ, de Josselin de Jong E, Jongebloed WL, Retief DH (1988). A model to investigate xerostomia-related dental caries. Caries Res22:357–361.
56.
Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J (1999). Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol162:5173–5177.
57.
Kawahara K, Iwamoto Y, Nikai H (1985). The use of trypsin for immunohistochemical localization of IgA-producing cells in mouse salivary glands. Hiroshima Daigaku Shigaku Zasshi17:327–331 [article in Japanese].
58.
Kerakawauchi H, Kurono Y, Mogi G (1997). Immune responses against Streptococcus pyogenes in human palatine tonsils. Laryngoscope107:634–639.
59.
Krasse B, Gahnberg L, Bratthall D (1978). Antibodies reacting with Streptococcus mutans in secretions from minor salivary glands in humans. Adv Exp Med Biol107:349–354.
60.
Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M (1998). A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses14:1625–1633.
61.
Lamey PJ, Nolan A, Follett EA, Coote I, MacFarlane TW, Kennedy DH, et al. (1996). Anti-HIV antibody in saliva: an assessment of the role of the components of saliva, testing methodologies and collection systems. J Oral Pathol Med25:104–107.
62.
Lamm ME, Phillips-Quagliata JM (2002). Origin and homing of intestinal IgA antibody-secreting cells. J Exp Med195:F5–F8.
63.
Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC (2003). A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol170:3799–3805.
64.
Lehmann JC, Jablonski-Westrich D, Haubold U, Gutierrez-Ramos JC, Springer T, Hamann A (2003). Overlapping and selective roles of endothelial intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 in lymphocyte trafficking. J Immunol171:2588–2593.
65.
Leigh JE, Steele C, Wormley FL Jr, Luo W, Clark RA, Gallaher W, et al. (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol19:373–380.
66.
Lin AL, Johnson DA, Stephan KT, Yeh CK (2003). Alteration in salivary function in early HIV infection. J Dent Res82:719–724.
67.
Liu X, Zha J, Chen H, Nishitani J, Camargo P, Cole SW, et al. (2003). Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. J Virol77:3470–3476.
68.
Lu FX (2000a). Predominate HIV1-specific IgG activity in various mucosal compartments of HIV-1-infected individuals. Clin Immunol97:59–68.
69.
Lu FX (2000b). New method for quantifying anti-HIV 1-gp160 antibodies in saliva, cervicovaginal secretions, and serum of infected women. J Clin Lab Anal14:188–192.
70.
Lü X, Grangeot-Keros L, Blot A, Rannou MT, Delfraissy JF, Pillot J (1993). Comparison of saliva and serum for HIV antibody testing. In: IXth International Conference on AIDS, Berlin, Germany, June 7–11. Abstract #PO-B40–2457.
71.
Lü X, Delfraissy JF, Grangeot-Keros L, Rannou MT, Pillot J (1994). Rapid and constant detection of HIV antibody response in saliva of HIV-infected patients; selective distribution of anti-HIV activity in the IgG isotype. Res Virol145:369–377.
72.
Lu Y, Pauza CD, Lu X, Montefiori DC, Miller CJ (1998). Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol19:6–18.
73.
Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B (1999). Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine17:2036–2042.
74.
Lundholm P, Leandersson AC, Christensson B, Bratt G, Sandstrom E, Wahren B (2002). DNA mucosal HIV vaccine in humans. Virus Res82:141–145.
75.
Maher D, Wu X, Schacker T, Larson M, Southern P (2004). A model system of oral HIV exposure, using human palatine tonsil, reveals extensive binding of HIV infectivity, with limited progression to primary infection. J Infect Dis190:1989–1997.
76.
Maher DM, Zhang ZQ, Schacker TW, Southern PJ (2005). Ex vivo modeling of oral HIV transmission in human palatine tonsil. J Histochem Cytochem53:631–642.
77.
Matthews JB, Potts AJ, Basu MK (1985). Immunoglobulin-containing cells in normal human labial salivary glands. Int Arch Allergy Appl Immunol77:374–376.
78.
McGhee JR, Kiyono H (1993). New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis2:55–73.
79.
McGhee JR, Michalek SM, Kiyono H, Eldridge JH, Colwell DE, Williamson SI, et al. (1984). Mucosal immunoregulation: environmental lipopolysaccharide and GALT T lymphocytes regulate the IgA response. Microbiol Immunol28:261–280.
80.
McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H (1992). The mucosal immune system: from fundamental concepts to vaccine development. Vaccine10:75–88.
81.
McGhee JR, Xu-Amano J, Miller CJ, Jackson RJ, Fujihashi K, Staats HF, et al. (1994). The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract. Reprod Fertil Dev6:369–379.
82.
Mega J, McGhee JR, Kiyono H (1995). Characterization of cytokine producing T cells, TCR expression, and IgA plasma cells in salivary gland-associated tissues. Adv Exp Med Biol371(B):1103–1108.
83.
Mestecky J, Kutteh WH, Jackson S (1994a). Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res Hum Retroviruses10(Suppl 2):S11–S20.
84.
Mestecky J, Walker MC, Mathieson BJ, Walker BD (1994b). Conference on advances in AIDS vaccine development—1993. Summary: Mucosal Immunity Workshop. AIDS Res Hum Retroviruses10(Suppl 2):S165–S170.
85.
Miller CJ, Lu FX (2003). Anti-HIV and -SIV immunity in the vagina. Int Rev Immunol22:65–76.
86.
Miller CJ, Alexander NJ, Sutjipto S, Lackner AA, Gettie A, Hendrickx AG, et al. (1989). Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol63:4277–4284.
87.
Miller CJ, McGhee JR, Gardner MB (1993). Mucosal immunity, HIV transmission, and AIDS. Lab Invest68:129–145.
88.
Miller CJ, McChesney MB, Lü X (1996). Mucosal immune responses to SIV infection. Semin Virol7:139–145.
89.
Miller CJ, McChesney MB, Lü X, Daily PJ, Chutkowski C, Lu D, et al. (1997). Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol71:1911–1921.
90.
Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, et al. (2003). Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol170:3906–3914.
91.
Montgomery PC, Rafferty DE (1998). Induction of secretory and serum antibody responses following oral administration of antigen with bioadhesive degradable starch microparticles. Oral Microbiol Immunol13:139–149.
92.
Moro I, Umemura S, Crago SS, Mestecky J (1984). Immunohistochemical distribution of immunoglobulins, lactoferrin, and lysozyme in human minor salivary glands. J Oral Pathol13:97–104.
93.
Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM (1998). Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis178:1635–1641.
94.
Nair PN, Schroeder HE (1983). Local immune response to repeated topical antigen application in the simian labial mucosa. Infect Immun41:399–409.
95.
Navazesh M, Mulligan R, Komaroff E, Redford M, Greenspan D, Phelan J (2000). The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res79:1502–1507.
96.
Nave H, Gebert A, Pabst R (2001). Morphology and immunology of the human palatine tonsil. Anat Embryol (Berl)204:367–373.
97.
Noble B, Gorfien J, Frankel S, Rossman J, Brodsky L (1996). Microanatomical distribution of dendritic cells in normal tonsils. Acta Otolaryngol Suppl523:94–97.
98.
O’Sullivan NL, Skandera CA, Montgomery PC (2001). Lymphocyte lineages at mucosal effector sites: rat salivary glands. J Immunol166:5522–5529.
99.
Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A, et al. (2003). Longitudinal study of mucosal candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis188:118–127.
100.
Okada H, Murakami S (1998). Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med9:248–266.
101.
Okunseri C, Badner V, Wiznia A, Rosenberg M (2003). Prevalence of oral lesions and percent CD4+ T-lymphocytes in HIV-infected children on antiretroviral therapy. AIDS Patient Care STDS17:5–11.
102.
Olofsson K, Hellström S, Hammarström ML (1998). The surface epithelium of recurrent infected palatine tonsils is rich in gammadelta T cells. Clin Exp Immunol111:36–47.
103.
Ooi SE, Tsai CY, Chou CT (2005). Interstitial lung disease and xerostomia as initial manifestations in a patient with human immunodeficiency virus infection. J Microbiol Immunol Infect38:145–148.
104.
Ørstavik TB, Carretero OA, Hayashi H, Scicli GA, Johansen L (1982). Immunohistochemical localization of tonin and its relation to kallikrein in rat salivary glands. J Histochem Cytochem30:1123–1129.
105.
Otten K, Dragoo J, Wang HC, Klein JR (2003). Antigen-induced chemokine activation in mouse buccal epithelium. Biochem Biophys Res Commun304:36–40.
Perry ME (1994). The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat185(Pt 1):111–127.
108.
Piazza M, Chirianni A, Picciotto L, Cataldo PT, Borgia G, Orlando R (1994). Blood in saliva of patients with acquired immunodeficiency syndrome: possible implication in sexual transmission of the disease. J Med Virol42:38–41.
109.
Pimpinelli N, Borgognoni L, Riccardi R, Ficarra G, Mori M, Gaglioti D, et al. (1991). CD36(OKM5)+ dendritic cells in the oral mucosa of HIV-and HIV+ subjects. J Invest Dermatol97:537–542.
110.
Pinto A, De Rossi SS (2004). Salivary gland disease in pediatric HIV patients: an update. J Dent Child (Chic)71:33–37.
111.
Quiding-Jarbrink M, Granström G, Nordström I, Holmgren J, Czerkinsky C (1995). Induction of compartmentalized B-cell responses in human tonsils. Infect Immun63:853–857.
112.
Reibel J, Dabelsteen E, Kenrad B, Buschard K (1985). Pattern of distribution of T lymphocytes, Langerhans cells and HLA-DR bearing cells in normal human oral mucosa. Scand J Dent Res93:513–521.
113.
Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA100:4144–4149.
Rott LS, Briskin MJ, Butcher EC (2000). Expression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites. J Leukoc Biol68:807–814.
116.
Salles MW, Middleton DM (2000). Lymphocyte subsets in porcine tonsillar crypt epithelium. Vet Immunol Immunopathol77:133–144.
Sankar V, Baccaglini L, Sawdey M, Wheeler CJ, Pillemer SR, Baum BJ, et al. (2002). Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses. Oral Dis8:275–281.
119.
Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC (2002). Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J Invest Dermatol118:652–657.
120.
Schaller M, Boeld U, Oberbauer S, Hamm G, Hube B, Korting HC (2004). Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology150:2807–2813.
121.
Schiødt M, Lackner A, Armitage G, Lerche N, Greenspan JS, Lowenstine L (1988). Oral lesions in rhesus monkeys associated with infection by simian AIDS retrovirus, serotype-I (SRV-1). Oral Surg Oral Med Oral Pathol65:50–55.
122.
Schiødt M, Greenspan D, Daniels TE, Nelson J, Leggott PJ, Wara DW, et al. (1989). Parotid gland enlargement and xerostomia associated with labial sialadenitis in HIV-infected patients. J Autoimmun2:415–425.
123.
Shine NR, Wang SC, Konopka K, Burks EA, Duzgunes N, Whitman CP (2002). Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg Chem30:249–263.
124.
Shugars DC (1999). Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis179(Suppl 3):S431–S435.
125.
Shugars DC, Patton LL, Freel SA, Gray LR, Vollmer RT, Eron JJ Jr, et al. (2001). Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. J Dent Res80:414–420.
Sozmen M, Brown PJ, Cripps PJ (1996). IgA, IgG and IgM immunohistochemical staining in normal dog salivary glands and in cases of chronic sialadenitis. Vet Res27:285–294.
128.
Springer TA (1990). Leucocyte adhesion to cells. Scand J Immunol32:211–216.
129.
Steele C, Fidel PL Jr (2002). Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immun70:577–583.
130.
Sweet SP, Rahman D, Challacombe SJ (1995). IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology86:556–559.
131.
Thibodeau L, Tremblay C, Lachapelle L (1991). Oral and parenteral immunization with HIV immunosome induce the secretion of IgA specific of HIV-1 in the salivary and the production of circulatory IgA in mice and rabbits. C R Acad Sci III313:389–394.
132.
Thrane PS, Sollid LM, Haanes HR, Brandtzaeg P (1992). Clustering of IgA-producing immunocytes related to HLA-DR-positive ducts in normal and inflamed salivary glands. Scand J Immunol35:43–51.
133.
Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M, et al. (2002). Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod93:149–154.
134.
Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC (2004). Salivary gland genetic vaccination: a scalable technology for promoting distal mucosal immunity and heightened systemic immune responses. Vaccine22:2500–2504.
135.
Underdown BJ (2005). Parenteral immunization induces mucosal protection: a challenge to the mucosal immunity paradigm. In: Mucosal immunology. 3rd ed. Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Amsterdam: Elsevier/Academic Press, pp. 831–840.
136.
van den Akker R, van den Hoek JA, van den Akker WM, Kooy H, Vijge E, Roosendaal G, et al. (1992). Detection of HIV antibodies in saliva as a tool for epidemiological studies. AIDS6:953–957.
137.
van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK (2001). Antiviral activities of lactoferrin. Antiviral Res52:225–239.
138.
van Loon LA, Krieg SR, Davidson CL, Bos JD (1989). Quantification and distribution of lymphocyte subsets and Langerhans cells in normal human oral mucosa and skin. J Oral Pathol Med18:197–201.
139.
Vernier A, Diab M, Soell M, Haan-Archipoff G, Beretz A, Wachsmann D, et al. (1996). Cytokine production by human epithelial and endothelial cells following exposure to oral viridans streptococci involves lectin interactions between bacteria and cell surface receptors. Infect Immun64:3016–3022.
140.
Viney JL, Jones S, Chiu HH, Lagrimas B, Renz ME, Presta LG, et al. (1996). Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol157:2488–2497.
141.
Walker DM (2004). Oral mucosal immunology: an overview. Ann Acad Med Singapore33(4 Suppl):27–30.
142.
Wu X, Jackson S (2000). Plasma and salivary IgG subclasses in HIV type 1 infection: evidence of both transudation and local synthesis of IgG in parotid saliva. AIDS Res Hum Retroviruses16:1423–1431.
143.
Wu Z, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, et al. (2003). Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses19:201–209.
144.
Yamamoto T, Osaki T, Yoneda K, Ueta E (1994). Cytokine production by keratinocytes and mononuclear infiltrates in oral lichen planus. J Oral Pathol Med23:309–315.
145.
Yoshino N, Lu FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, et al. (2004). A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J Immunol173:6850–6857.
146.
Younai FS, Marcus M, Freed JR, Coulter ID, Cunningham W, Der-Martirosian C, et al. (2001). Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod92:629–636.
147.
Youngman KR, Lazarus NH, Butcher EC (2005). Lymphocyte homing: chemokines and adhesion molecules in T cell and IgA plasma cell localization in the mucosal immune system. In: Mucosal immunology. 3rd ed. Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Amsterdam: Elsevier/Academic Press, pp. 667–680.
148.
Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ (2002a). Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol168:1796–1803.
149.
Zuercher AW, Jiang HQ, Thurnheer MC, Cuff CF, Cebra JJ (2002b). Distinct mechanisms for cross-protection of the upper versus lower respiratory tract through intestinal priming. J Immunol169:3920–3925.
